Enhanced Antiretroviral Therapy in Rhesus Macaques Improves RT-SHIV Viral Decay Kinetics

被引:9
作者
North, Thomas W. [1 ,2 ,3 ]
Villalobos, Andradi [1 ]
Hurwitz, Selwyn J. [1 ,2 ]
Deere, Jesse D. [3 ]
Higgins, Joanne [3 ]
Chatterjee, Payel [1 ,2 ]
Tao, Sijia [1 ,2 ]
Kauffman, Robert C. [3 ]
Luciw, Paul A. [3 ]
Kohler, James J. [1 ,2 ]
Schinazi, Raymond F. [1 ,2 ]
机构
[1] Emory Univ, Ctr AIDS Res, Sch Med, Atlanta, GA 30322 USA
[2] Atlanta Vet Affairs Med Ctr, Decatur, GA USA
[3] Univ Calif Davis, Davis, CA 95616 USA
关键词
SIMIAN IMMUNODEFICIENCY VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; NONHUMAN PRIMATE MODEL; COMBINATION THERAPY; ANIMAL-MODEL; HIV; TYPE-1; AIDS; PHARMACOKINETICS; ERADICATION;
D O I
10.1128/AAC.02522-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Using an established nonhuman primate model, rhesus macaques were infected intravenously with a chimeric simian immunodeficiency virus (SIV) consisting of SIVmac239 with the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase from clone HXBc2 (RT-SHIV). The impacts of two enhanced (four- and five-drug) highly active antiretroviral therapies (HAART) on early viral decay and rebound were determined. The four-drug combination consisted of an integrase inhibitor, L-870-812 (L-812), together with a three-drug regimen comprising emtricitabine [(-)-FTC], tenofovir (TFV), and efavirenz (EFV). The five-drug combination consisted of one analog for each of the four DNA precursors {using TFV, (-)-FTC, (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diaminopurine (amdoxovir [DAPD]), and zidovudine (AZT)}, together with EFV. A cohort treated with a three-drug combination of (-)-FTC, TFV, and EFV served as treated controls. Daily administration of a three-, four-, or five-drug combination of antiretroviral agents was initiated at week 6 or 8 after inoculation and continued up to week 50, followed by a rebound period. Plasma samples were collected routinely, and drug levels were monitored using liquid chromatography-tandem mass spectrometry (LC-MS-MS). Viral loads were monitored with a standard TaqMan quantitative reverse transcriptase PCR (qRT-PCR) assay. Comprehensive analyses of replication dynamics were performed. RT-SHIV infection in rhesus macaques produced typical viral infection kinetics, with untreated controls establishing persistent viral loads of >10(4) copies of RNA/ml. RT-SHIV loads at the start of treatment (V-o) were similar in all treated cohorts (P > 0.5). All antiretroviral drug levels were measureable in plasma. The four-drug and five-drug combination regimens (enhanced HAART) improved suppression of the viral load (within 1 week; P < 0.01) and had overall greater potency (P < 0.02) than the three-drug regimen (HAART). Moreover, rebound viremia occurred rapidly following cessation of any treatment. The enhanced HAART (four- or five-drug combination) showed significant improvement in viral suppression compared to the three-drug combination, but no combination was sufficient to eliminate viral reservoirs.
引用
收藏
页码:3927 / 3933
页数:7
相关论文
共 42 条
[31]   Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1 [J].
North, TW ;
Van Rompay, KKA ;
Higgins, J ;
Matthews, TB ;
Wadford, DA ;
Pedersen, NC ;
Schinazi, RF .
JOURNAL OF VIROLOGY, 2005, 79 (12) :7349-7354
[32]   Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy [J].
Palmer, Sarah ;
Malclarelli, Frank ;
Wiegand, Ann ;
Bernstein, Barry ;
Hanna, George J. ;
Brun, Scott C. ;
Kempf, Dale J. ;
Mellors, John W. ;
Coffin, John M. ;
King, Martin S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (10) :3879-3884
[33]   Decay characteristics of HIV-1-infected compartments during combination therapy [J].
Perelson, AS ;
Essunger, P ;
Cao, YZ ;
Vesanen, M ;
Hurley, A ;
Saksela, K ;
Markowitz, M ;
Ho, DD .
NATURE, 1997, 387 (6629) :188-191
[34]   Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence [J].
Press, N ;
Tyndall, MW ;
Wood, E ;
Hogg, RS ;
Montaner, JSG .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 :S112-S117
[35]   The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases [J].
Rausch, DM ;
Murray, EA ;
Eiden, LE .
JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 65 (04) :466-474
[36]   COMBINATIONS OF ISOPRINOSINE AND 3'-AZIDO-3'-DEOXYTHYMIDINE IN LYMPHOCYTES INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 [J].
SCHINAZI, RF ;
CANNON, DL ;
ARNOLD, BH ;
MARTINOSALTZMAN, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (12) :1784-1787
[37]   Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase [J].
Sharma, PL ;
Nurpeisov, V ;
Hernandez-Santiago, B ;
Beltran, T ;
Schinazi, RF .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (09) :895-919
[38]   A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model [J].
Shytaj, Iart Luca ;
Norelli, Sandro ;
Chirullo, Barbara ;
Della Corte, Alessandro ;
Collins, Matt ;
Yalley-Ogunro, Jake ;
Greenhouse, Jack ;
Iraci, Nunzio ;
Acosta, Edward P. ;
Barreca, Maria Letizia ;
Lewis, Mark G. ;
Savarino, Andrea .
PLOS PATHOGENS, 2012, 8 (06)
[39]   A nucleotide substitution in the tRNALys primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase [J].
Soderberg, K ;
Denekamp, L ;
Nikiforow, S ;
Sautter, K ;
Desrosiers, RC ;
Alexander, L .
JOURNAL OF VIROLOGY, 2002, 76 (11) :5803-5806
[40]   ANIMAL-MODEL FOR THE THERAPY OF ACQUIRED-IMMUNODEFICIENCY-SYNDROME WITH REVERSE-TRANSCRIPTASE INHIBITORS [J].
UBERLA, K ;
STAHLHENNIG, C ;
BOTTIGER, D ;
MATZRENSING, K ;
KAUP, FJ ;
LI, J ;
HASELTINE, WA ;
FLECKENSTEIN, B ;
HUNSMANN, G ;
OBERG, B ;
SODROSKI, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (18) :8210-8214